Cargando…

Risk Factors for the Prescription of Ineffective Antiviral Candidates for COVID-19 During the Early Pandemic Period in Korea

BACKGROUND: Although the evidence of treatment for coronavirus disease 2019 (COVID-19) changed rapidly, little is known about the patterns of potential pharmacological treatment during the early period of the COVID-19 pandemic in Korea and the risk factors for ineffective prescription. METHODS: Usin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Eunyoung, Kim, Seungyeon, Lee, Sun Young, Jeong, Joo, Bang, Jihwan, Oh, Juhwan, Shin, Sang Do, Kim, Nam Joong, Choe, Pyoeng Gyun, Oh, Myoung-don
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497349/
https://www.ncbi.nlm.nih.gov/pubmed/37698205
http://dx.doi.org/10.3346/jkms.2023.38.e280
_version_ 1785105288061255680
author Lee, Eunyoung
Kim, Seungyeon
Lee, Sun Young
Jeong, Joo
Bang, Jihwan
Oh, Juhwan
Shin, Sang Do
Kim, Nam Joong
Choe, Pyoeng Gyun
Oh, Myoung-don
author_facet Lee, Eunyoung
Kim, Seungyeon
Lee, Sun Young
Jeong, Joo
Bang, Jihwan
Oh, Juhwan
Shin, Sang Do
Kim, Nam Joong
Choe, Pyoeng Gyun
Oh, Myoung-don
author_sort Lee, Eunyoung
collection PubMed
description BACKGROUND: Although the evidence of treatment for coronavirus disease 2019 (COVID-19) changed rapidly, little is known about the patterns of potential pharmacological treatment during the early period of the COVID-19 pandemic in Korea and the risk factors for ineffective prescription. METHODS: Using claims data from the Korean National Health Insurance System, this retrospective cohort study included admission episodes for COVID-19 from February to December 2020. Ineffective antiviral prescriptions for COVID-19 were defined as lopinavir/ritonavir (LPN/r) and hydroxychloroquine (HCQ) prescribed after July 2020, according to the revised National Institute of Health COVID-19 treatment guidelines. Factors associated with ineffective prescriptions, including patient and hospital factors, were identified by multivariate logistic regression analysis. RESULTS: Of the 15,723 COVID-19 admission episodes from February to June 2020, 4,183 (26.6%) included prescriptions of LPN/r, and 3,312 (21.1%) included prescriptions of HCQ. Of the 48,843 admission episodes from July to December 2020, after the guidelines were revised, 2,258 (4.6%) and 182 (0.4%) included prescriptions of ineffective LPN/r and HCQ, respectively. Patient factors independently associated with ineffective antiviral prescription were older age (adjusted odds ratio [aOR] per 10-year increase, 1.17; 95% confidence interval [CI], 1.14–1.20) and severe condition with an oxygen requirement (aOR, 2.49; 95% CI, 2.24–2.77). The prescription of ineffective antiviral drugs was highly prevalent in primary and nursing hospitals (aOR, 40.58; 95% CI, 31.97–51.50), public sector hospitals (aOR, 15.61; 95% CI, 12.76–19.09), and regions in which these drugs were highly prescribed before July 2020 (aOR, 10.65; 95% CI, 8.26–13.74). CONCLUSION: Ineffective antiviral agents were prescribed to a substantial number of patients during the first year of the COVID-19 pandemic in Korea. Treatment with these ineffective drugs tended to be prolonged in severely ill patients and in primary and public hospitals.
format Online
Article
Text
id pubmed-10497349
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Korean Academy of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-104973492023-09-13 Risk Factors for the Prescription of Ineffective Antiviral Candidates for COVID-19 During the Early Pandemic Period in Korea Lee, Eunyoung Kim, Seungyeon Lee, Sun Young Jeong, Joo Bang, Jihwan Oh, Juhwan Shin, Sang Do Kim, Nam Joong Choe, Pyoeng Gyun Oh, Myoung-don J Korean Med Sci Original Article BACKGROUND: Although the evidence of treatment for coronavirus disease 2019 (COVID-19) changed rapidly, little is known about the patterns of potential pharmacological treatment during the early period of the COVID-19 pandemic in Korea and the risk factors for ineffective prescription. METHODS: Using claims data from the Korean National Health Insurance System, this retrospective cohort study included admission episodes for COVID-19 from February to December 2020. Ineffective antiviral prescriptions for COVID-19 were defined as lopinavir/ritonavir (LPN/r) and hydroxychloroquine (HCQ) prescribed after July 2020, according to the revised National Institute of Health COVID-19 treatment guidelines. Factors associated with ineffective prescriptions, including patient and hospital factors, were identified by multivariate logistic regression analysis. RESULTS: Of the 15,723 COVID-19 admission episodes from February to June 2020, 4,183 (26.6%) included prescriptions of LPN/r, and 3,312 (21.1%) included prescriptions of HCQ. Of the 48,843 admission episodes from July to December 2020, after the guidelines were revised, 2,258 (4.6%) and 182 (0.4%) included prescriptions of ineffective LPN/r and HCQ, respectively. Patient factors independently associated with ineffective antiviral prescription were older age (adjusted odds ratio [aOR] per 10-year increase, 1.17; 95% confidence interval [CI], 1.14–1.20) and severe condition with an oxygen requirement (aOR, 2.49; 95% CI, 2.24–2.77). The prescription of ineffective antiviral drugs was highly prevalent in primary and nursing hospitals (aOR, 40.58; 95% CI, 31.97–51.50), public sector hospitals (aOR, 15.61; 95% CI, 12.76–19.09), and regions in which these drugs were highly prescribed before July 2020 (aOR, 10.65; 95% CI, 8.26–13.74). CONCLUSION: Ineffective antiviral agents were prescribed to a substantial number of patients during the first year of the COVID-19 pandemic in Korea. Treatment with these ineffective drugs tended to be prolonged in severely ill patients and in primary and public hospitals. The Korean Academy of Medical Sciences 2023-08-17 /pmc/articles/PMC10497349/ /pubmed/37698205 http://dx.doi.org/10.3346/jkms.2023.38.e280 Text en © 2023 The Korean Academy of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lee, Eunyoung
Kim, Seungyeon
Lee, Sun Young
Jeong, Joo
Bang, Jihwan
Oh, Juhwan
Shin, Sang Do
Kim, Nam Joong
Choe, Pyoeng Gyun
Oh, Myoung-don
Risk Factors for the Prescription of Ineffective Antiviral Candidates for COVID-19 During the Early Pandemic Period in Korea
title Risk Factors for the Prescription of Ineffective Antiviral Candidates for COVID-19 During the Early Pandemic Period in Korea
title_full Risk Factors for the Prescription of Ineffective Antiviral Candidates for COVID-19 During the Early Pandemic Period in Korea
title_fullStr Risk Factors for the Prescription of Ineffective Antiviral Candidates for COVID-19 During the Early Pandemic Period in Korea
title_full_unstemmed Risk Factors for the Prescription of Ineffective Antiviral Candidates for COVID-19 During the Early Pandemic Period in Korea
title_short Risk Factors for the Prescription of Ineffective Antiviral Candidates for COVID-19 During the Early Pandemic Period in Korea
title_sort risk factors for the prescription of ineffective antiviral candidates for covid-19 during the early pandemic period in korea
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497349/
https://www.ncbi.nlm.nih.gov/pubmed/37698205
http://dx.doi.org/10.3346/jkms.2023.38.e280
work_keys_str_mv AT leeeunyoung riskfactorsfortheprescriptionofineffectiveantiviralcandidatesforcovid19duringtheearlypandemicperiodinkorea
AT kimseungyeon riskfactorsfortheprescriptionofineffectiveantiviralcandidatesforcovid19duringtheearlypandemicperiodinkorea
AT leesunyoung riskfactorsfortheprescriptionofineffectiveantiviralcandidatesforcovid19duringtheearlypandemicperiodinkorea
AT jeongjoo riskfactorsfortheprescriptionofineffectiveantiviralcandidatesforcovid19duringtheearlypandemicperiodinkorea
AT bangjihwan riskfactorsfortheprescriptionofineffectiveantiviralcandidatesforcovid19duringtheearlypandemicperiodinkorea
AT ohjuhwan riskfactorsfortheprescriptionofineffectiveantiviralcandidatesforcovid19duringtheearlypandemicperiodinkorea
AT shinsangdo riskfactorsfortheprescriptionofineffectiveantiviralcandidatesforcovid19duringtheearlypandemicperiodinkorea
AT kimnamjoong riskfactorsfortheprescriptionofineffectiveantiviralcandidatesforcovid19duringtheearlypandemicperiodinkorea
AT choepyoenggyun riskfactorsfortheprescriptionofineffectiveantiviralcandidatesforcovid19duringtheearlypandemicperiodinkorea
AT ohmyoungdon riskfactorsfortheprescriptionofineffectiveantiviralcandidatesforcovid19duringtheearlypandemicperiodinkorea